The Next Frontier in Oncology Discovery
Matching the Right Target, Modality, and Patient:
As oncology drug discovery becomes increasingly modality-rich and biologically complex, one question is more important than ever: How do you match the right target, modality, assay strategy, and patient population to maximize the probability of success?
In our latest article, inspired by the expert panel discussion at the WuXi AppTec Spring Science Forum, we explore how the oncology landscape is evolving beyond traditional small molecules and monoclonal antibodies toward a broader therapeutic toolbox that now includes:
🔹 Targeted protein degraders and molecular glues
🔹 ADCs and multispecific antibodies
🔹 Radioligands, peptides, and macrocycles
Our experts discuss how today’s oncology programs increasingly require a systems-level understanding of cancer biology, disciplined modality selection, and integrated decision-making across biology, chemistry, assay strategy, DMPK, formulation, and development planning.
WuXi AppTec’s integrated CRDMO platform can help innovators navigate this growing complexity by connecting discovery biology, medicinal chemistry, screening technologies, assay development, DMPK, formulation, and development expertise within a unified framework. By integrating these capabilities early, teams can make more informed decisions, reduce technical uncertainty, and accelerate the path from target hypothesis to high-quality development candidates.
